

# Phase I Clinical Trial of the CYP17 Inhibitor Abiraterone Acetate Demonstrating Clinical Activity in Patients With Castration-Resistant Prostate Cancer Who Received Prior Ketoconazole Therapy

Charles J. Ryan, Matthew R. Smith, Lawrence Fong, Jonathan E. Rosenberg, Philip Kantoff, Florence Raynaud, Vanessa Martins, Gloria Lee, Thian Kheoh, Jennifer Kim, Arturo Molina, and Eric J. Small

See accompanying editorial on page 1447 and articles on pages 1489 and 1496

From the Urologic Oncology Program, University of California, San Francisco; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco; Cougar Biotechnology, Los Angeles, CA; Massachusetts General Hospital; Dana-Farber Cancer Institute, Lank Center for Genitourinary Oncology, Boston, MA; and Institute of Cancer Research, Drug Metabolism and Pharmacokinetics Team, Belmont, Sutton, United Kingdom.

Submitted May 15, 2009; accepted August 21, 2009; published online ahead of print at [www.jco.org](http://www.jco.org) on February 16, 2010.

Supported by Cougar Biotechnology, the Department of Defense Prostate Cancer Clinical Trials Consortium, and Grant No. K23CA115775 (C.J.R.) from the National Institutes of Health. V.M. and F.R. are employees of The Institute of Cancer Research, which has a commercial interest in the development of abiraterone and operates a rewards to inventors scheme. The Institute of Cancer Research has been involved in a commercial collaboration with Cougar Biotechnology.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

Clinical Trials repository link available on [JCO.org](http://JCO.org).

Corresponding author: Charles J. Ryan, MD, Associate Professor of Clinical Medicine, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, 1600 Divisadero St, San Francisco, CA 94115; e-mail: [ryanc@medicine.ucsf.edu](mailto:ryanc@medicine.ucsf.edu).

© 2010 by American Society of Clinical Oncology

0732-183X/10/2809-1481/\$20.00

DOI: 10.1200/JCO.2009.24.1281

## ABSTRACT

### Purpose

Abiraterone acetate is a prodrug of abiraterone, a selective inhibitor of CYP17, the enzyme catalyst for two essential steps in androgen biosynthesis. In castration-resistant prostate cancers (CRPCs), extragonadal androgen sources may sustain tumor growth despite a castrate environment. This phase I dose-escalation study of abiraterone acetate evaluated safety, pharmacokinetics, and effects on steroidogenesis and prostate-specific antigen (PSA) levels in men with CRPC with or without prior ketoconazole therapy.

### Patients and Methods

Thirty-three men with chemotherapy-naïve progressive CRPC were enrolled. Nineteen patients (58%) had previously received ketoconazole for CRPC. Bone metastases were present in 70% of patients, and visceral involvement was present in 18%. Three patients (9%) had locally advanced disease without distant metastases. Fasted or fed cohorts received abiraterone acetate doses of 250, 500, 750, or 1,000 mg daily. Single-dose pharmacokinetic analyses were performed before continuous daily dosing.

### Results

Adverse events were predominantly grade 1 or 2. No dose-limiting toxicities were observed. Hypertension (grade 3, 12%) and hypokalemia (grade 3, 6%; grade 4, 3%) were the most frequent serious toxicities and responded to medical management. Confirmed  $\geq 50\%$  PSA declines at week 12 were seen in 18 (55%) of 33 patients, including nine (47%) of 19 patients with prior ketoconazole therapy and nine (64%) of 14 patients without prior ketoconazole therapy. Substantial declines in circulating androgens and increases in mineralocorticoids were seen with all doses.

### Conclusion

Abiraterone acetate was well tolerated and demonstrated activity in CRPC, including in patients previously treated with ketoconazole. Continued clinical study is warranted.

*J Clin Oncol* 28:1481-1488. © 2010 by American Society of Clinical Oncology

## INTRODUCTION

Androgen deprivation therapy is the standard of care for patients with advanced prostate cancer. However, virtually all patients eventually develop castration-resistant prostate cancer (CRPC), the lethal form of prostate cancer where less than 20% of men survive beyond 3 years.<sup>1-3</sup>

Historically, castration-resistant tumors were thought to have no reliance on androgen receptor (AR) signaling for growth and survival, prompting characterization as androgen independent

or hormone resistant. However, recent findings suggest that AR signaling persists in many of these tumors,<sup>4-7</sup> the result of adaptive mechanisms that permit survival in the castrate-level androgen environment.<sup>8-10</sup>

Although medical or surgical androgen deprivation abrogates gonadal testosterone production, circulating testosterone of up to 10% of precastrate levels may persist as a result of androgen production from the adrenal glands or the tumor itself.<sup>10</sup> Through its inhibitory action on the cholesterol side-chain cleavage enzyme as well as CYP17,

ketoconazole has demonstrated activity as a secondary hormonal manipulation in CRPC. In a phase III clinical trial in metastatic CRPC, 28% of patients treated with ketoconazole experienced a  $\geq 50\%$  decline in prostatic-specific antigen (PSA), and the median survival time was approximately 16 months. Notably, progression of disease on this study was shown to be associated with an increase in adrenal androgen levels, indicating a failure of the drug to durably suppress hormone production.<sup>11</sup>

Abiraterone acetate and its metabolite, abiraterone, are potent and selective inhibitors of CYP17  $\alpha$ -hydroxylase and C<sub>17,20</sub>-lyase activities, both essential steps in androgen biosynthesis. In human microsomes, the concentration of abiraterone required to produce 50% inhibition of CYP17 is approximately 10% that of ketoconazole.<sup>12,13</sup> The current report details findings from a phase I trial of abiraterone acetate in men with CRPC both with and without prior ketoconazole therapy and provides important insights into the endocrinologic and clinical effects of potent CYP17 inhibition.

## PATIENTS AND METHODS

### Major Eligibility Criteria

Men with histologically confirmed adenocarcinoma of the prostate and disease progression despite androgen deprivation therapy (either a luteinizing hormone–releasing hormone agonist or orchiectomy) were eligible. When appropriate, progression after antiandrogen withdrawal was required. Patients with metastatic disease or PSA-only progression by the PSA Working Group criteria<sup>14</sup> were eligible. Prior chemotherapy for prostate cancer was not allowed. Use of other hormonal therapies, systemic corticosteroids, or any other product known to decrease PSA levels was not permitted within 4 weeks of treatment initiation. Eligibility required an Eastern Cooperative Oncology Group performance status of 0 or 1, serum creatinine  $\leq 1.5 \times$  the institutional upper limit of normal [ULN], bilirubin  $\leq 1. \times$  ULN, AST and ALT  $\leq 2.5 \times$

ULN, serum potassium  $\geq 3.5$  mmol/L, and baseline adrenocorticotropic hormone (ACTH) stimulation test peak cortisol level of more than 18  $\mu\text{g/dL}$ . Patients with uncontrolled hypertension, New York Heart Association Class III or IV congestive heart failure, autoimmune disease requiring corticosteroid therapy, or other illness interfering with study participation were ineligible. Prior ketoconazole therapy was not required for eligibility for the study.

### Study Design and Treatment

The primary objective of this phase I, dose-escalation trial was determination of the maximum-tolerated dose (MTD) of abiraterone acetate administered orally on a continuous schedule in men with CRPC with and without prior ketoconazole therapy. Endocrine and pharmacokinetic effects were secondary objectives. The study was approved by the institutional review boards of the participating institutions and was conducted in accordance with the ethical principles of the World Medical Association Declaration of Helsinki. All patients provided written informed consent.

Medical maintenance of a castrate testosterone level was required for patients without prior orchiectomy. Abiraterone acetate was administered orally as a 250-mg tablet in escalating dose cohorts of 250, 500, 750, and 1,000 mg, with fed and fasted cohorts enrolled at each dose. On day –7, patients were administered a single dose of abiraterone acetate for pharmacokinetic analysis after an overnight fast or 30 minutes after starting a 800- to 1,000-calorie breakfast.<sup>15</sup> After 7 days, drug was administered daily.

Dose-limiting toxicity (DLT) was defined as any drug-related grade  $\geq 3$  toxicity by the Common Terminology Criteria for Adverse Events (version 3) observed in the first 28 days. Neither fatigue responding to corticosteroid replacement nor grade 3 hypertension manageable with mineralocorticoid antagonists or corticosteroids was considered dose limiting. A single DLT event would expand a cohort to six patients, two DLT events would de-escalate to a lower dose cohort, and more than two DLTs among six patients would stop escalation and define the prior dose level as the MTD. Continuation of therapy beyond 28 days was allowed at the discretion of the physician.<sup>14,15</sup>

Use of a glucocorticoid was allowed for patients with clinical symptoms of adrenal insufficiency and fatigue, whereas mineralocorticoid excess could receive the aldosterone antagonists. Spironolactone was not permitted because of its potential to act as an AR agonist.<sup>16</sup>

**Table 1.** Patient Demographics and Clinical Characteristics

Characteristic	Total Patients (N = 33)	Abiraterone Acetate Dose			
		250 mg (n = 6)	500 mg (n = 9)	750 mg (n = 6)	1,000 mg (n = 12)
Age, years					
Median	72	65	71	74	76
Range	56-85	61-76	56-76	63-85	59-83
ECOG performance status, No. of patients					
0	30	5	9	6	10
1	3	1	0	0	2
PSA, ng/mL					
Median	33	35	45	29	28
Range	7-5,436	16-98	8-5,436	12-205	7-451
Gleason score, No. of patients					
< 7	5	1	1	0	3
7	13	1	2	4	6
> 7	15	4	6	2	3
Disease involvement, No. of patients					
Elevated PSA	33	6	9	6	12
Prostate	14	1	2	4	7
Lymph node	11	2	2	2	5
Bone	23	5	6	5	7
Viscera	6	0	3	1	2
Prior ketoconazole therapy, No. of patients	19	5	7	1	6

Abbreviations: ECOG, Eastern Cooperative Oncology Group; PSA, prostate-specific antigen.

## Evaluations

Baseline evaluations included a history, examination, CBC counts and serum chemistries, PSA, serum testosterone, assessment of adrenal steroidogenesis (ACTH, luteinizing hormone, follicle-stimulating hormone, corticosterone, cortisol, 11-deoxycorticosterone, 11-deoxycortisol, aldosterone, and dehydroepiandrosterone sulfate [DHEA-S]), and imaging studies as clinically indicated. Testosterone levels were measured by a commercial assay method (liquid chromatography–tandem mass spectrometry, lower limit of quantitation of 1.0 ng/dL; Quest Diagnostics, Madison, NJ). Evaluations were repeated weekly throughout the first cycle of therapy and before day 1 of any subsequent cycles. Imaging studies were repeated at cycles 4, 7, and 10, as clinically warranted. Clinical activity was evaluated using PSA decline parameters according to PSA Working Group criteria.<sup>14</sup>

## Pharmacokinetic Analysis

Blood samples for pharmacokinetic analysis were collected at hours 1, 2, 4, 8, 12, 24, and 48 after single-dose administration of abiraterone acetate on day -7, before dosing on days 1, 8, 15, and 22 of cycle 1, and before the first dose of any subsequent cycles. Abiraterone acetate and abiraterone plasma concentrations were analyzed by a liquid chromatography–tandem mass spectrometry assay developed and performed by the Institute of Cancer Research Drug Metabolism and Pharmacokinetics Team (Belmont, Sutton, United Kingdom). The assays were validated and linear within the range of 5 to 500 nmol/L. Noncompartmental pharmacokinetic analyses were performed using WINNonlin (Scientific Consultant, Apex, NC) software. Estimated parameters included maximum concentration ( $C_{max}$ ), time of maximum observed concentration, terminal half-life, total body apparent clearance, apparent volume of distribution ( $V_d$ ), and area under the curve (AUC) from the time of dosing to the last measurable concentration ( $AUC_{last}$ ) and extrapolated to infinity ( $AUC_{0-\infty}$ ).

## Patient Characteristics

Between July 2006 and December 2007, 33 patients with CRPC were enrolled (Table 1). Seventy percent had bone metastasis, 18% had visceral involvement, and three patients (9%) had locally advanced disease without distant metastases. Nineteen patients (58%) had received prior ketoconazole therapy for CRPC. The median duration of ketoconazole therapy was 15 months (range, 1.6 to 42 months), and 16 (84%) of 19 patients had achieved a  $\geq 50\%$  decline in PSA on ketoconazole. The median interval from the date of discontinuation of ketoconazole until beginning therapy with abiraterone was 7.0 months (range, 1.8 to 31 months). Of the 19 patients, ketoconazole had been discontinued in 15 patients (79%) because of disease progression and in four patients (21%) because of toxicity.

## Dose Escalation

Tolerability was acceptable through 1,000 mg daily in both fasted and fed patients, and no DLTs were observed. The 500-mg dose cohort was expanded to include three additional patients (total of six patients in the fasted cohort) after one patient treated at this dose level experienced a syncopal event that was subsequently determined to be unrelated to study therapy. This type of event was not observed in subsequent patients. On the basis of evidence of clinical responses across several doses, maximization of the intended endocrinologic effects, and the favorable safety, dose

**Table 2.** Incidence of Most Common (> 10%) Adverse Events of Abiraterone Acetate in Patients With Castration-Resistant Prostate Cancer

Adverse Event	All Grades (N = 33)		Dose Cohort (No. of patients)								
			250 mg (n = 6)		500 mg (n = 9)		750 (n = 6)		1,000 mg (n = 12)		
			Grade 1/2	Grade 3	Grade 1/2	Grade 3/4	Grade 1/2	Grade 3	Grade 1/2	Grade 3	
Abdominal pain	6	18	1		2			2		1	
Constipation	7	21			2	1		2			2
Diarrhea	10	30			3			2	1		4
Dry mouth	7	21			2			3			2
Dyspepsia	4	12			2			2			
Nausea	11	33	1		3			1			6
Vomiting	5	15			1			1			3
Asthenia	8	24	1		3			2			2
Fatigue	22	67	3		7			4			8
Edema	5	15	1		3						1
Peripheral edema	8	24			2						6
Anorexia	7	21	1		2			1			3
Hyperglycemia	4	12	1		1						2
Hypokalemia	8	24				1		3	1		2
Arthralgia	5	15	1					2			1
Back pain	4	12	1		1			1			1
Muscular weakness	5	15	2		1			1	1		
Dizziness	5	15			1			2			2
Headache	11	33			3			2			6
Cough	7	21	1		1			4			1
Hot flush	7	21			2			2			3
Hypertension	12	36	2		1	1		2	1		3
Hypotension	4	12	1		3						2

escalation was ceased at 1,000 mg. These findings paralleled a concurrent study with abiraterone acetate.<sup>16</sup>


### Toxicity

The most common adverse events were fatigue, hypertension, headache, nausea, and diarrhea (Table 2). Adverse events were predominantly grade 1 or 2. Grade 3 toxicities consisted of hypertension (n = 4), hypokalemia (n = 2), constipation (n = 1), diarrhea (n = 1), muscular weakness (n = 1), and arthralgia (n = 1). One patient treated at the 500-mg dose level developed grade 4 hypokalemia. The three episodes of grade 3 or 4 hypokale-

mia all occurred after cycle 1. Only one episode of grade 1 hypokalemia occurred in cycle 1. There was no observed increase in toxicity in patients who had previously been treated with ketoconazole. Grade 3 or 4 toxicities occurred in seven (37%) of 19 patients with prior ketoconazole exposure and in six (55%) of 11 patients without prior ketoconazole exposure.

### Endocrine Effects

As predicted, therapy with abiraterone acetate resulted in a substantial reduction of circulating androgen levels and an increase in mineralocorticoids such as deoxycorticosterone, upstream of CYP17



**Fig 1.** Changes in mean levels of endocrine steroids from baseline to day 28 of therapy, by dose (A-C), in men with castration-resistant prostate cancer receiving abiraterone acetate. DHEA-S, dehydroepiandrosterone sulfate.

(Fig A1, online only). A decrease in cortisol was observed (Fig 1). DHEA-S and testosterone levels decreased to undetectable or near undetectable levels. At the 1,000-mg dose level, the DHEA-S level decreased from baseline values (mean, 49  $\mu\text{g}/\text{dL}$ ; range, 15 to 99  $\mu\text{g}/\text{dL}$ ) to  $\leq 15$   $\mu\text{g}/\text{dL}$  (assay lower limit of quantitation) at day 28 and remained at this level at time of progression. For testosterone, corresponding mean values were 4 ng/dL (range, 1 to 10 ng/dL) at baseline and  $\leq 1$  ng/dL (range, 1 to 2 ng/dL) at day 28; values remained at  $\leq 1$  ng/dL (range, 1 to 1.5 ng/dL) at time of progression (Fig 2). A possible trend in dose-response relationship was observed for deoxycorticosterone, corticosterone, and 11-deoxycortisol levels, although statistical comparison is limited by the small total number. No appreciable changes in follicle-stimulating hormone or luteinizing hormone levels were seen.

### Pharmacokinetics

Pharmacokinetics were evaluated for all 33 patients. Abiraterone acetate was not detected in any sample, suggesting rapid conversion to abiraterone. Maximum drug concentrations ( $C_{\text{max}}$ ) were achieved within 1.5 to 4 hours (time of maximum observed concentration; Table 3). Less than proportional increases in both  $C_{\text{max}}$  and  $\text{AUC}_{0-\infty}$  were observed across dose levels in fed and fasted patients (Table 3; Fig A2, online only) but were less pronounced among fed patients. The small number of patients per cohort and the high degree of interpatient variability, often approaching 50%, limit further interpretation. Nonetheless, abiraterone exposures appeared higher in fed patients (Fig A3, online only), possibly suggesting that food may increase absorption. Terminal half-life ranged from 5 to 14 hours. At subse-


quent cycles, concentrations were lower (approximately 10% to 15%) than the highest concentration observed in cycle 1.

### Efficacy

At week 12, confirmed decreases in PSA levels of  $\geq 50\%$  were seen in 18 (55%) of 33 patients overall, including nine (47%) of 19 patients with prior ketoconazole therapy and nine (64%) of 14 patients without prior ketoconazole therapy (Fig 3). A maximal PSA decrease of  $\geq 50\%$  at any time point was seen in 19 (58%) of 33 patients, including 10 patients (53%) with prior ketoconazole exposure and nine patients (64%) without. At 1,000 mg, seven (58%) of 12 patients had a  $\geq 50\%$  maximal decrease in PSA. Within the prior ketoconazole group, confirmed  $\geq 50\%$  decreases in PSA were seen in two (50%) of four patients who had discontinued ketoconazole as a result of toxicity and in seven (47%) of 15 patients who had discontinued ketoconazole as a result of disease progression. The median time to PSA progression for all patients was 234 days (95% CI, 174 to 341 days). Among patients with and without prior ketoconazole, median time to PSA progression was 283 days (95% CI, 174 days to not estimable) and 230 days (95% CI, 90 to 341 days), respectively (Fig A4, online only).

Nine (56%) of 16 patients who previously responded to ketoconazole responded to abiraterone. Seven (37%) of 19 patients who responded to ketoconazole did not respond to abiraterone.

Of three patients who did not respond to ketoconazole, one has responded to abiraterone. Of four patients who discontinued ketoconazole as a result of toxicity, three responded to abiraterone. Of the 15 patients who developed ketoconazole-refractory disease (eg, experienced progression of disease on ketoconazole after experiencing a response), seven (46%) responded to abiraterone.



**Fig 2.** Relative levels of (A) dehydroepiandrosterone sulfate and (B) testosterone (commercial assay) at baseline, at day 28, and at the time of disease progression in patients treated with abiraterone acetate, by dose.

## DISCUSSION

Abiraterone acetate has significant activity in patients with CRPC, as evidenced by a PSA response rate of 58% in this phase I trial and declines in PSA on all dose levels. Although the utility of using PSA reductions as a marker of clinical activity is debated, in general, most investigators agree that it is a reasonable tool to screen for activity. The activity of abiraterone acetate is attributed to the reduction of the total androgen pool, with a reduction in levels of both adrenal androgens and testosterone, thereby inhibiting persistent signaling through the AR. It is of considerable interest that abiraterone acetate has demonstrated activity in patients previously treated with ketoconazole.

Dose escalation was not discontinued as a result of the presence of DLTs. Abiraterone acetate was well tolerated up through the highest dose level evaluated (1,000 mg/d) with no MTD observed and no apparent toxicity differences among patients who had or had not received prior ketoconazole use. On the basis of safety, endocrinologic and pharmacokinetic parameters, and indications of activity, an abiraterone acetate dose of 1,000 mg/d is recommended for further study.

The adverse event and steroid endocrine profiles were consistent with anticipated outcomes of selective CYP17 inhibition (decrease in androgens and concomitant increase in upstream mineralocorticoid production). At the 1,000-mg dose level, hypertension and fatigue were the most commonly observed toxicities. The use of beta-blockers, diuretics, and eplerenone (often at doses  $> 25$  mg daily) was modestly effective in managing abiraterone-induced hypertension.



# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.